Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
$0.79
+97.3%
$0.49
$0.25
$1.00
$5.74M-1.2456 shs8 shs
iBio, Inc. stock logo
IBIO
iBio
$0.85
+1.5%
$0.74
$0.56
$6.89
$16.57M0.861.49 million shs132,682 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21457,628 shsN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
+8.6%
$0.00
$0.00
$0.10
$2.10M1.08121,484 shs8,466 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
+0.03%+97.26%+61.84%+164.33%-20.70%
iBio, Inc. stock logo
IBIO
iBio
-2.57%+2.81%+40.15%-13.30%-55.47%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%-50.00%0.00%0.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-30.00%+133.33%+66.67%-41.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
$0.79
+97.3%
$0.49
$0.25
$1.00
$5.74M-1.2456 shs8 shs
iBio, Inc. stock logo
IBIO
iBio
$0.85
+1.5%
$0.74
$0.56
$6.89
$16.57M0.861.49 million shs132,682 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21457,628 shsN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
+8.6%
$0.00
$0.00
$0.10
$2.10M1.08121,484 shs8,466 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
+0.03%+97.26%+61.84%+164.33%-20.70%
iBio, Inc. stock logo
IBIO
iBio
-2.57%+2.81%+40.15%-13.30%-55.47%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%-50.00%0.00%0.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-30.00%+133.33%+66.67%-41.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
0.00
N/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00491.72% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, CPMV, IBIO, and SRNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/AN/AN/AN/A($0.94) per shareN/A
iBio, Inc. stock logo
IBIO
iBio
$375K44.29N/AN/A$1.41 per share0.60
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$440K0.00N/A0.08N/ANaN
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.03N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
-$920K-$0.10N/AN/AN/AN/A-822.45%11/17/2025 (Estimated)
iBio, Inc. stock logo
IBIO
iBio
-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$8.18MN/A0.00N/AN/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest NPHC, CPMV, IBIO, and SRNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2025Q2 2025
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/A-$0.02N/A-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/A
0.01
0.01
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/A
iBio, Inc. stock logo
IBIO
iBio
7.90%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
80.99%
iBio, Inc. stock logo
IBIO
iBio
0.58%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
37.24 million1.38 millionNot Optionable
iBio, Inc. stock logo
IBIO
iBio
10019.66 million9.82 millionN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
Sorrento Therapeutics Inc (SRNE)
Sorrento Therapeutics Inc SRNE
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
Sorrento Therapeutics
5 Sanders Cove, Sorrento WA 6020

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mosaic ImmunoEngineering stock logo

Mosaic ImmunoEngineering OTCMKTS:CPMV

$0.79 +0.39 (+97.26%)
As of 09/8/2025

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

iBio stock logo

iBio NYSE:IBIO

$0.84 +0.01 (+1.46%)
As of 10:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0038 +0.00 (+8.57%)
As of 09:30 AM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.